the aid library

LIST OPTIONS

Filter

4723

European Drug Report 2019: trends and developments.

European Monitoring Centre for Drugs and Drug Addiction European Union (2019) C1

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ... more

Download (250)

View PDF (399)

Nurses as substitutes for doctors in primary care - Review

Laurant M, van der Biezen M, Wijers N et al. Cochrane Library (2018) CC

Current and expected problems such as ageing, increased prevalence of chronic conditions and multi-morbidity, increased emphasison healthy lifestyle and prevention, and substitution for care from hospitals by care provided in the community encourage countries worldwide to develop new models of prima... more

Download (1415)

View PDF (1227)

The Haiti Health Sector Directory: U.S.-Based Implementers Working in Haiti

USAID, Synergie Project (2003) C1

Download (641)

View PDF (1693)

Framework for a national plan for monitoring and management of insecticide resistance in malaria vectors

World Health Organization (WHO) (2017) C_WHO

Effective malaria prevention is threatened by widespread and increasing vector insecticide resistance. Failure to mitigate this threat will likely result in an increased burden of disease, with significant cost implications. This new framework provides support for the development of a national insec... more

Download (825)

View PDF (1841)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (422)

View PDF (645)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (276)

View PDF (347)

Checklist for assessing quality of healthcare - Hospitals

Kenya Ministry of Health (2021) C1

Kenya Quality Model for Health - Hospitals

Download (1898)

View PDF (6313)

Hand Hygiene Technical Reference Manual

World Health Organization WHO (2009) CC

A manual to train health-care workers on practising, teaching and observing hand hygiene.

External Link

Essential Package of Health Services (EPHS). Secondary & Tertiary Care: The District, County & National Health Systems (Liberia)
recommended

Ministry of Health & Social Welfare, Liberia (2011) C1

Essential Drug list on page 36!!

Download (817)

View PDF (1444)

Prevenção da potencial transmissão do vírus Zika por via sexual
recommended

Organização Mundial da Saùde (2016) C_WHO

Actualização das orientações provisórias 7 de Junho de 2016

Download (1034)

View PDF (1303)

WHO recommendations for prevention and treatment of maternal peripartum infections

World Health Organization WHO (2015) C_WHO

Download (652)

View PDF (1154)

Tanzania: HIV Care and Treatment Plan 2003-2008

The William J. Clinton Foundation Ministry of Health, Tanzania (2003) C1

Download (413)

View PDF (672)

India: TRAINING OF Link ART Centre (LAC) COUNSELLORS - HANDBOOK FOR TRAINEES

National AIDS Control Organization (NACO), Ministry of Health and Family Welfare, Government of India (2012) C1

Download (316)

View PDF (431)

Tuberculoses à bacilles résistants : diagnostic et prise en charge

Haut Conseil de la Santé Publique (2014) C2

Lignes directrices. Collection Avis et Rapports.

Download (264)

View PDF (769)

Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis

Centers for Disease Control and Prevention (2013) C_CDC

MMWR: Recommendations and Reports / Vol. 62 / No. 9 Morbidity and Mortality Weekly Report October 25, 2013

Download (344)

View PDF (681)

Relevance of CBR and Inclusive Development in Post 2015 Agenda

Thomas, M. and Ninomiya, A. CBR Asia-Pacific Network (2015) C1

Download (277)

View PDF (352)

Rwanda Annual Report on HIV and AIDS, 2010-2011

Ministry of Health, Rwanda & Rwanda Biomedical Centre (2011) C2

The 2010-2011 National Annual Report on HIV program presents the progress in implementing the strategies and activities articulated in the National Strategic Plan on HIV and AIDS 2009-2012 commonly referred to as the HIV NSP. The report presents consolidated information regarding the outputs in the ... more